A Study to Learn About the Study Medicine Called Tilrekimig ( PF-07275315) in People With Severe Asthma

Summary

The purpose of this clinical study is to learn about the safety and effects of the study medicine (called tilrekimig) for the potential treatment of severe asthma. Asthma is a condition that makes it challenging to breathe, which negatively impacts the quality of life of people who are affected. The study is seeking participants who: Have a history of severe asthma for at least 12 months Have had at least 2 asthma attacks (also known as exacerbations) within the last 12 months All participants will be given shots of study medicine or a placebo at the study clinic.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• Asthma

Eligibility basics and study details

Study type

Interventional

Phase

Phase 3

Ages

12 to 80 years

Sex

All

Healthy volunteers

Not accepted

Sponsor

Pfizer

Last updated on ClinicalTrials.gov

November 5, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites